Article: Managed care & medical oncology: the focus is on value.
Journal of the National Comprehensive Cancer Network : JNCCN
2010 Volume 8 Suppl 7, Page(s) S28–37
Abstract: A previous NCCN Oncology Insights Reportdescribed the factors making cancer care a priority for managed care organizations (MCOs) and emerging trends in managing costs of cancer care. To better understand the concerns of MCOs and how they are addressing ... ...
| Abstract | A previous NCCN Oncology Insights Reportdescribed the factors making cancer care a priority for managed care organizations (MCOs) and emerging trends in managing costs of cancer care. To better understand the concerns of MCOs and how they are addressing cancer costs and quality, NCCN interviewed senior physician executives from the 3 largest payors in the United States. The interviews provided insights into how these companies managed oncology care, with an emphasis on drugs and biologics. As a follow-up to the previous report, NCCN conducted additional interviews with medical executives from 10 MCOs between February and April 2010. The organizations represented in these interviews were Aetna, BlueCross BlueShield of Minnesota, BlueShield of Michigan, CareFirst BlueCross BlueShield, Empire BlueCross BlueShield, HealthNow, Humana, Independence BlueCross, Priority Health, and UnitedHealthcare. Although this group is diverse, it does not constitute a representative cross-section of MCOs across the United States. NCCN interviewed these executives about the priority of cancer care management for their organizations and the strategies being used to address cost and quality of cancer care. The information garnered from these interviews was qualitative in nature. A separate quantitative analysis of trends in oncology managed care has already been published, and throughout this report, data from the 2009-2010 Genentech Oncology Trend Report are referenced to supplement findings from the NCCN interviews. |
|---|---|
| MeSH term(s) | Antineoplastic Agents/economics ; Antineoplastic Agents/therapeutic use ; Community Participation ; Comparative Effectiveness Research ; Drug Costs ; Health Care Costs ; Health Care Reform ; Humans ; Insurance Coverage ; Insurance, Health ; Interviews as Topic ; Managed Care Programs/economics ; Managed Care Programs/standards ; Medical Oncology/economics ; Medication Adherence ; Neoplasms/economics ; Neoplasms/therapy ; Patient Participation ; Physician Executives ; Quality of Health Care ; Reimbursement Mechanisms/organization & administration ; Reimbursement Mechanisms/trends ; United States |
| Chemical Substances | Antineoplastic Agents |
| Language | English |
| Publishing date | 2010-10-08 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2250759-0 |
| ISSN | 1540-1405 |
| ISSN | 1540-1405 |
| DOI | 10.6004/jnccn.2010.0132 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 6365: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.